|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.30 USD | -0.72% |
|
-1.87% | -0.87% |
| Jan. 17 | Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks | MT |
| Jan. 17 | USA: 15 new drugs on the negotiation list | CF |
| Capitalization | 149B 143B 135B 121B 213B 12,849B 238B 1,644B 609B 5,301B 559B 547B 23,201B | P/E ratio 2024 * |
15x | P/E ratio 2025 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 207B 199B 188B 169B 297B 17,869B 331B 2,286B 847B 7,372B 777B 761B 32,266B | EV / Sales 2024 * |
3.29x | EV / Sales 2025 * | 3.19x |
| Free-Float |
59.04% | Yield 2024 * |
6.34% | Yield 2025 * | 6.46% |
More valuation ratios
* Estimated data
More news
Last Transcript: Pfizer, Inc.
More recommendations
More press releases
More news
| 1 day | -0.72% | ||
| 1 week | -1.87% | ||
| Current month | -0.87% | ||
| 1 month | -0.23% | ||
| 3 months | -9.99% | ||
| 6 months | -12.25% | ||
| Current year | -0.87% |
1 week
25.96
26.65
1 month
25.9627.57
Current year
25.9627.57
1 year
24.4831.54
3 years
24.4856.32
5 years
24.4861.71
10 years
24.4861.71
| Director | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 63 | 2018-12-31 |
David Denton
DFI | Director of Finance/CFO | 60 | 2022-05-01 |
Lidia Fonseca
CTO | Chief Tech/Sci/R&D Officer | 56 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 67 | 2007-08-31 |
Helen Hobbs
BRD | Director/Board Member | 72 | 2011-12-11 |
Shantanu Narayen
BRD | Director/Board Member | 61 | 2013-09-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 335 M€ | -2.98% | - | |
| 9.37% | 30 M€ | +1.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.72% | -1.87% | -7.00% | -51.34% | 149B | ||
| -4.21% | -9.00% | +15.45% | +198.49% | 653B | ||
| -0.50% | +1.77% | -9.06% | -11.03% | 354B | ||
| +1.52% | -10.08% | -24.73% | +73.23% | 341B | ||
| -1.23% | -2.93% | +4.12% | +28.96% | 303B | ||
| -2.76% | -3.03% | -17.64% | +21.26% | 248B | ||
| -0.07% | +0.76% | +9.34% | -26.90% | 236B | ||
| +0.20% | -0.26% | +2.72% | +22.08% | 206B | ||
| +0.35% | -1.72% | -4.87% | +9.63% | 197B | ||
| +0.99% | +0.71% | -11.60% | +18.88% | 146B | ||
| Average | -0.66% | -1.83% | -4.33% | +28.33% | 283.38B | |
| Weighted average by Cap. | -1.20% | -3.21% | -1.98% | +56.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 63.05B 60.63B 57.24B 51.26B 90.29B 5,436B 101B 695B 258B 2,243B 236B 232B 9,816B | 63.02B 60.6B 57.21B 51.23B 90.23B 5,433B 101B 695B 258B 2,241B 236B 231B 9,810B |
| Net income | 10.12B 9.73B 9.18B 8.22B 14.48B 872B 16.15B 112B 41.35B 360B 37.94B 37.16B 1,575B | 13.24B 12.73B 12.02B 10.76B 18.96B 1,141B 21.14B 146B 54.11B 471B 49.65B 48.63B 2,061B |
| Net Debt | 58.23B 55.99B 52.86B 47.34B 83.38B 5,020B 92.99B 642B 238B 2,071B 218B 214B 9,065B | 52.28B 50.27B 47.46B 42.5B 74.85B 4,507B 83.48B 577B 214B 1,859B 196B 192B 8,138B |
More financial data
* Estimated data
Employees
88,000
Sector
Pharmaceuticals
Calendar
2025-01-23
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-17 | 26.30 $ | -0.72% | 35,380,330 |
| 25-01-16 | 26.49 $ | +1.03% | 29,981,137 |
| 25-01-15 | 26.22 $ | -0.72% | 35,949,694 |
| 25-01-14 | 26.41 $ | -1.46% | 25,856,913 |
Delayed Quote Nyse, January 17, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
26.30USD
Average target price
31.18USD
Spread / Average Target
+18.54%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
